| Peer-Reviewed

Vitiligo and Treatment

Received: 31 August 2015     Accepted: 9 November 2015     Published: 3 December 2015
Views:       Downloads:
Abstract

Background: Vitiligo is a common skin condition resulting from loss of normal melanin pigments in the skin which produces white patches. It mainly affects a younger population and can cause serious cosmetic and social problems. At least three theories about the underlying mechanism of vitiligo have been proposed. Release of a chemical that is toxic to melanocytes is one theory, while another theory says that the melanocytes simply self-destruct. According to the third theory, vitiligo is a type of autoimmune disease. Methods: We performed a prospective study to evaluate the efficacy of the 0.05% clobetasol propionate and 1% pimecrolimus in the treatment of vitiligo. In our study is 25 patients with virtually lesions of vitiligo. Results: Results from this pilot study indicate that topical 1% pimecrolimus is as effective as clobetasol propionate in restoring skin disfiguring due to vitiligo. Discussion: Further studies investigating the safety and efficacy of topical 1% pimecrolimus ointment either as monotherapy or in combination with other therapeutic measures are warranted.

Published in Clinical Medicine Research (Volume 4, Issue 6)
DOI 10.11648/j.cmr.20150406.15
Page(s) 195-197
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2015. Published by Science Publishing Group

Keywords

Vitiligo, the Skin Dispigmentation, Progress in Treatment of Vitiligo

References
[1] Mosher DB, Fitzpatrick TB, Ortonne JP, Hori Y. Hypomelanoses and hypermelanoses. In: Freedberg IM, Eisen AZ, Wolff K, et al., eds. Dermatology in General Medicine. 5th ed. New York: McGraw Hill, 1999: 949-60.
[2] Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003; 17: 493-503.
[3] Marsland AM, Griffiths CE. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002; 12(6): 618-22.
[4] Luger T. Treatment of immune-mediated skin diseases: future perspectives. Eur J Dermatol 2001; 11(4): 343-7.
[5] Mrowietz U. Macrolide immunosuppressants. Eur J Dermatol 1999; 9(5): 346-51.
[6] Hartmann A, Brocker EB, Becker JC. Hypopigmentary skin disorders: current treatment options and future directions. Drugs 2004; 64: 89-107.
[7] Mayoral FA, Gonzalez C, Shah NS, Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003; 207: 322-3.
[8] Vancoillie G, Lambert J, Nayaert JM. Melanocyte biology and its implications for the clinician. Eur J Dermatol 1999; 9(3): 241-51.
[9] Kostovic K, Nola I, Bucan Z, Situm M. Treatment of vitiligo: current methods and new approaches. Acta Dermatovenerol Croat 2003; 11: 163-70.
[10] Bos JD. Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis. Eur J Dermatol 2003; 13(5): 455-61.
[11] Ongenae K, Van Geel N, De Schepper S, Vander Haeghen Y, Naeyaert JM. Management of vitiligo patients and attitude of dermatologists towards vitiligo. Eur J Dermatol 2004; 14(3): 177-81.
[12] Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol 1984; 120: 631-5.
[13] Geraldez CB, Gutierrez GT. A clinical trial of clobetasol propionate in Filipino vitiligo patients. Clin Ther 1987; 9: 474-82.
[14] Clayton R. A double-blind trial of 0-05lobetasol proprionate in the treatment of vitiligo. Br J Dermatol 1977; 96: 71-3.
[15] Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05lobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-5.
[16] Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003; 139: 571-4.
[17] Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789-91.
[18] Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus. Dermatology 2002; 205: 301-3.
[19] Tanghetti EA. Tacrolimus ointment 0.10roduces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003; 71: 158-62.
Cite This Article
  • APA Style

    Sadije Halimi, Mybera Ferizi, Antigona Gerqari, Nita Krasniqi, Mergita Ferizi. (2015). Vitiligo and Treatment. Clinical Medicine Research, 4(6), 195-197. https://doi.org/10.11648/j.cmr.20150406.15

    Copy | Download

    ACS Style

    Sadije Halimi; Mybera Ferizi; Antigona Gerqari; Nita Krasniqi; Mergita Ferizi. Vitiligo and Treatment. Clin. Med. Res. 2015, 4(6), 195-197. doi: 10.11648/j.cmr.20150406.15

    Copy | Download

    AMA Style

    Sadije Halimi, Mybera Ferizi, Antigona Gerqari, Nita Krasniqi, Mergita Ferizi. Vitiligo and Treatment. Clin Med Res. 2015;4(6):195-197. doi: 10.11648/j.cmr.20150406.15

    Copy | Download

  • @article{10.11648/j.cmr.20150406.15,
      author = {Sadije Halimi and Mybera Ferizi and Antigona Gerqari and Nita Krasniqi and Mergita Ferizi},
      title = {Vitiligo and Treatment},
      journal = {Clinical Medicine Research},
      volume = {4},
      number = {6},
      pages = {195-197},
      doi = {10.11648/j.cmr.20150406.15},
      url = {https://doi.org/10.11648/j.cmr.20150406.15},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20150406.15},
      abstract = {Background: Vitiligo is a common skin condition resulting from loss of normal melanin pigments in the skin which produces white patches. It mainly affects a younger population and can cause serious cosmetic and social problems. At least three theories about the underlying mechanism of vitiligo have been proposed. Release of a chemical that is toxic to melanocytes is one theory, while another theory says that the melanocytes simply self-destruct. According to the third theory, vitiligo is a type of autoimmune disease. Methods: We performed a prospective study to evaluate the efficacy of the 0.05% clobetasol propionate and 1% pimecrolimus in the treatment of vitiligo. In our study is 25 patients with virtually lesions of vitiligo. Results: Results from this pilot study indicate that topical 1% pimecrolimus is as effective as clobetasol propionate in restoring skin disfiguring due to vitiligo. Discussion: Further studies investigating the safety and efficacy of topical 1% pimecrolimus ointment either as monotherapy or in combination with other therapeutic measures are warranted.},
     year = {2015}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Vitiligo and Treatment
    AU  - Sadije Halimi
    AU  - Mybera Ferizi
    AU  - Antigona Gerqari
    AU  - Nita Krasniqi
    AU  - Mergita Ferizi
    Y1  - 2015/12/03
    PY  - 2015
    N1  - https://doi.org/10.11648/j.cmr.20150406.15
    DO  - 10.11648/j.cmr.20150406.15
    T2  - Clinical Medicine Research
    JF  - Clinical Medicine Research
    JO  - Clinical Medicine Research
    SP  - 195
    EP  - 197
    PB  - Science Publishing Group
    SN  - 2326-9057
    UR  - https://doi.org/10.11648/j.cmr.20150406.15
    AB  - Background: Vitiligo is a common skin condition resulting from loss of normal melanin pigments in the skin which produces white patches. It mainly affects a younger population and can cause serious cosmetic and social problems. At least three theories about the underlying mechanism of vitiligo have been proposed. Release of a chemical that is toxic to melanocytes is one theory, while another theory says that the melanocytes simply self-destruct. According to the third theory, vitiligo is a type of autoimmune disease. Methods: We performed a prospective study to evaluate the efficacy of the 0.05% clobetasol propionate and 1% pimecrolimus in the treatment of vitiligo. In our study is 25 patients with virtually lesions of vitiligo. Results: Results from this pilot study indicate that topical 1% pimecrolimus is as effective as clobetasol propionate in restoring skin disfiguring due to vitiligo. Discussion: Further studies investigating the safety and efficacy of topical 1% pimecrolimus ointment either as monotherapy or in combination with other therapeutic measures are warranted.
    VL  - 4
    IS  - 6
    ER  - 

    Copy | Download

Author Information
  • Department of Dermatovenerology, University Clinical Centre of Kosovo, Pristina, Republic of Kosovo

  • Department of Dermatovenerology, University Clinical Centre of Kosovo, Pristina, Republic of Kosovo

  • Department of Dermatovenerology, University Clinical Centre of Kosovo, Pristina, Republic of Kosovo

  • University of Prishtina, Medical Faculty, Pristina, Republic of Kosovo

  • University of Prishtina, Medical Faculty, Pristina, Republic of Kosovo

  • Sections